Role of myeloid cells in oncolytic reovirus-based cancer therapy

Vishnupriyan Kumar, Michael A. Giacomantonio, Shashi Gujar

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

14 Citas (Scopus)

Resumen

Oncolytic reovirus preferentially targets and kills cancer cells via the process of oncolysis, and additionally drives clinically favorable antitumor T cell responses that form protective immunological memory against cancer relapse. This two-prong attack by reovirus on cancers constitutes the foundation of its use as an anticancer oncolytic agent. Unfortunately, the efficacy of these reovirus-driven antitumor effects is influenced by the highly suppressive tumor microenvironment (TME). In particular, the myeloid cell populations (e.g., myeloid-derived suppressive cells and tumor-associated macrophages) of highly immunosuppressive capacities within the TME not only affect oncolysis but also actively impair the functioning of reovirus-driven antitumor T cell immunity. Thus, myeloid cells within the TME play a critical role during the virotherapy, which, if properly understood, can identify novel therapeutic combination strategies potentiating the therapeutic efficacy of reovirus-based cancer therapy.

Idioma originalEnglish
Número de artículo654
PublicaciónViruses
Volumen13
N.º4
DOI
EstadoPublished - abr. 2021

Nota bibliográfica

Funding Information:
Funding: V.K. is supported through the Cancer Research Training Program (CRTP) of the Beatrice Hunter Cancer Research Institute (BHCRI), with funds provided by the Motorcycle Ride for Dad through the Dalhousie Medical Research Foundation (DMRF). M.A.G. is supported through the Cancer Research Training Program (CRTP) of Beatrice Hunter Cancer Research Institute (BHCRI), with funds provided by the QEII Health Sciences Centre Foundation and GIVETOLIVE Becky Beaton Award, the Nova Scotia Graduate Scholarship (NSGS), and Killam Doctoral Scholarship. S.G. is supported by research grants from Canadian Institutes for Health research (CIHR) and Dalhousie Medical Research Foundation (DMRF).

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

ASJC Scopus Subject Areas

  • Infectious Diseases
  • Virology

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Huella

Profundice en los temas de investigación de 'Role of myeloid cells in oncolytic reovirus-based cancer therapy'. En conjunto forman una huella única.

Citar esto